First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50

Cancer Immunology, Immunotherapy（2022）

引用 0|浏览0

暂无评分

摘要

Few real-world data are available in patients with advanced metastatic non-small cell lung cancer (NSCLC) treated with first-line immunotherapy, particularly in those with brain metastases at treatment initiation. This was a national, retrospective, multicenter study that consecutively included all patients with PD-L1-positive (tumor proportion score ≥ 50

查看译文

关键词

Pembrolizumab,Non-small cell lung cancer,Advanced stage,Brain metastases,Real-world study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要